All contributors
Onconephrology contributor
Nasr, Samih H
Primarily MGRS & paraprotein kidney disease#2 of 47 recognizedHonor roll
- #2 in MGRS & paraprotein kidney disease
84
Clinical papers
5,676
Citations (iCite)
20 / 24
First / senior author
2003–2026
Active years
Output over time
Clinical corpus papers per year — peak 11 in 2015.
- 2003: 1 paper
- 2004: 1 paper
- 2009: 1 paper
- 2011: 2 papers
- 2012: 6 papers
- 2013: 4 papers
- 2014: 4 papers
- 2015: 11 papers
- 2016: 4 papers
- 2017: 2 papers
- 2018: 7 papers
- 2019: 7 papers
- 2020: 5 papers
- 2021: 8 papers
- 2022: 5 papers
- 2023: 2 papers
- 2024: 5 papers
- 2025: 6 papers
- 2026: 3 papers
20032026
Subfield mix
Clinical papers by onconephrology subfield (a paper can count in more than one).
MGRS & paraprotein kidney disease73
Myeloma cast nephropathy39
Anticancer drug nephrotoxicity7
Onco-nephrology (general)1
Cellular therapy renal effects1
Checkpoint-inhibitor kidney injury1
Anti-VEGF / TKI renal effects1
Frequent collaborators
Other recognized contributors who most often share corpus papers with Nasr (shared-paper count).
Verify
Representative recent papers, and this author’s full PubMed bibliography.
A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,329-article corpus (regenerated 2026-08-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.